Jump to content

DS-1 (drug)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vaccinationist (talk | contribs) at 08:03, 7 December 2015. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

DS-1
Identifiers
  • 4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.209.966 Edit this at Wikidata
Chemical and physical data
FormulaC18H10Br2ClN3OS
Molar mass511.617 g/mol g·mol−1
3D model (JSmol)
  • s4cccc4-c2nc1c(Br)cc(Br)cn1c2NC(=O)c(cc3)ccc3Cl
  (verify)

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]

See also

References

  1. ^ Wafford, KA; Van Niel, MB; Ma, QP; Horridge, E; Herd, MB; Peden, DR; Belelli, D; Lambert, JJ (2009). "Novel compounds selectively enhance delta subunit containing GABA a receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200.
Stub icon

This sedative-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=DS-1_(drug)&oldid=694130434"